Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte1,2, Federico Cappuzzo3, Ihor Vynnychenko4, Daniil Stroyakovskiy5, Delvys Rodríguez-Abreu6, Maen Hussein7,8, Ross Soo9, Henry J. Conter10, Toshiyuki Kozuki11, Kuan-Chieh Huang12, Vilma Graupner13, Shawn W. Sun12, Tien Hoang12, Helen Jessop14, Mark McCleland12, Marcus Ballinger12, Alan Sandler12, Mark A. Socinski15
1Department of Medical Oncology, Rocky Mountain Cancer Centers, Denver, Colorado
2US Oncology, Houston, Texas
3Department of Oncology and Hematology, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy
4Department of Oncology and Radiology, Sumy State University, Sumy, Ukraine
5Chemotherapeutic Department, Moscow City Oncology Hospital, Moscow Healthcare Department, Moscow, Russia
6Department of Medical Oncology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain
7Department of Cancer Research, Florida Cancer Specialists, Lady Lake, Florida
8Sarah Cannon Research Institute, Nashville, Tennessee
9Department of Hematology-Oncology, National University Hospital, Singapore
10Department of Medicine, William Osler Health System, Brampton, Ontario, Canada
11National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
12Product Development, Oncology Genentech, Inc., South San Francisco, California
13Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland
14Department of Clinical Safety, Roche Products Ltd., Welwyn Garden City, United Kingdom
15Department of Thoracic Oncology, AdventHealth Cancer Institute, Orlando, Florida
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Journal of Thoracic Oncology
Tập 15
1351-1360
Thông tin tác giả